Clinical Trials Browser

Phase 2 × Mitomycin × 90 days × Clear all

NCT04929028 2026-03-18

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Phase 2 Recruiting

Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT06770582 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT05672108 2026-03-05

Phase II Trial of Lung Chemoemobolization

Phase 2 Recruiting

GastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Mediastinal Neoplasms, Pleural Neoplasms, Sarcoma

NCT04166318 2026-03-02

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Phase 2 Active not recruiting

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01815359 2026-02-05

ICARuS

Phase 2 Active not recruiting

Gastrointestinal

Appendiceal Neoplasms, Colorectal Neoplasms

NCT04779554 2025-12-24

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

Phase 2 Recruiting

GastrointestinalGynecologic

Appendiceal Neoplasms, Peritoneal Neoplasms, Pseudomyxoma Peritonei, Colorectal Neoplasms